📊 APTOF Key Takeaways
Is Aptose Biosciences Inc. (APTOF) a Good Investment?
Aptose Biosciences is in critical financial distress with negative stockholders' equity of -$19.4M, indicating liabilities exceed assets. The company generates zero revenue while burning $16.1M in annual operating cash flow, with only $613K in cash reserves and a current ratio of 0.53x indicating severe liquidity crisis. Continued operations appear unsustainable without significant capital infusion or strategic intervention.
Aptose Biosciences shows the typical profile of a highly speculative pre-revenue biotech, but its fundamentals are especially weak because it has no revenue, persistent operating and free cash flow losses, and negative stockholders' equity. While net loss and diluted EPS improved year over year, the balance sheet and liquidity position appear severely strained, with only $613K of cash against a roughly $16.15M annual operating cash burn.
Why Buy Aptose Biosciences Inc. Stock? APTOF Key Strengths
- Minimal capital expenditure ($5K) suggests focus on R&D rather than infrastructure spending
- Biotech sector positioning offers potential for transformative breakthroughs if pipeline succeeds
- No reportable long-term debt structure (though liabilities of $25.8M represent immediate concern)
- Net income loss improved 50.3% year over year
- Diluted EPS improved 84.0% year over year
- Capital expenditure needs are minimal, preserving cash for operations and development
APTOF Stock Risks: Aptose Biosciences Inc. Investment Risks
- Negative stockholders' equity of -$19.4M indicates technical insolvency and high bankruptcy risk
- Zero revenue generation with -$16.1M operating cash burn rate unsustainable with only $613K cash
- Current ratio of 0.53x and quick ratio of 0.53x signal acute liquidity crisis and inability to meet short-term obligations
- Deteriorating financial position despite 50.3% improvement in net loss suggests accounting adjustments rather than operational improvement
- No insider purchases in last 90 days suggests lack of management confidence
- No revenue base, making growth quality and commercial traction unproven
- Negative stockholders' equity and liabilities far exceeding assets indicate severe balance-sheet weakness
- Current ratio of 0.53x and very low cash relative to burn suggest major near-term liquidity and financing risk
Key Metrics to Watch
- Cash balance trend and runway (critical given monthly burn rate)
- Ability to raise capital or secure financing to extend runway
- Clinical trial progress and regulatory milestones for pipeline assets
- Liability restructuring or debt reduction initiatives
- Operating cash burn rate stabilization
- Cash balance and operating cash burn relative to runway
- Quarterly net loss trend and improvements in working capital/current ratio
Aptose Biosciences Inc. (APTOF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
APTOF Profit Margin, ROE & Profitability Analysis
APTOF vs Healthcare Sector: How Aptose Biosciences Inc. Compares
How Aptose Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aptose Biosciences Inc. Stock Overvalued? APTOF Valuation Analysis 2026
Based on fundamental analysis, Aptose Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aptose Biosciences Inc. Balance Sheet: APTOF Debt, Cash & Liquidity
APTOF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aptose Biosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-36.38 indicates the company is currently unprofitable.
APTOF Revenue Growth, EPS Growth & YoY Performance
APTOF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.1M | $-2.01 |
| Q2 2025 | N/A | -$7.0M | $-2.76 |
| Q1 2025 | N/A | -$5.5M | $-2.61 |
| Q3 2024 | N/A | -$7.0M | $-0.37 |
| Q2 2024 | N/A | -$7.3M | $-0.43 |
| Q1 2024 | N/A | -$9.6M | $-0.73 |
| Q3 2023 | N/A | -$9.8M | $-1.59 |
| Q2 2023 | N/A | -$10.6M | $-1.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aptose Biosciences Inc. Dividends, Buybacks & Capital Allocation
APTOF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aptose Biosciences Inc. (CIK: 0000882361)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APTOF
What is the AI rating for APTOF?
Aptose Biosciences Inc. (APTOF) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APTOF's key strengths?
Claude: Minimal capital expenditure ($5K) suggests focus on R&D rather than infrastructure spending. Biotech sector positioning offers potential for transformative breakthroughs if pipeline succeeds. ChatGPT: Net income loss improved 50.3% year over year. Diluted EPS improved 84.0% year over year.
What are the risks of investing in APTOF?
Claude: Negative stockholders' equity of -$19.4M indicates technical insolvency and high bankruptcy risk. Zero revenue generation with -$16.1M operating cash burn rate unsustainable with only $613K cash. ChatGPT: No revenue base, making growth quality and commercial traction unproven. Negative stockholders' equity and liabilities far exceeding assets indicate severe balance-sheet weakness.
What is APTOF's revenue and growth?
Aptose Biosciences Inc. reported revenue of $0.0.
Does APTOF pay dividends?
Aptose Biosciences Inc. does not currently pay dividends.
Where can I find APTOF SEC filings?
Official SEC filings for Aptose Biosciences Inc. (CIK: 0000882361) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APTOF's EPS?
Aptose Biosciences Inc. has a diluted EPS of $-7.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APTOF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aptose Biosciences Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APTOF stock overvalued or undervalued?
Valuation metrics for APTOF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APTOF stock in 2026?
Our dual AI analysis gives Aptose Biosciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APTOF's free cash flow?
Aptose Biosciences Inc.'s operating cash flow is $-16.1M, with capital expenditures of $5.0K.
How does APTOF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.53 (avg: 2).